PN-943
Protagonist Therapeutics, Inc.
['ibd']
no significant safety signals were noted; the 40-week extended treatment period (part 2 of the trial) is ongoing #uegweek #ibd #gitwitter 
The Lancet Gastroenterology & Hepatology publishes high-quality peer-reviewed research and reviews, comment, and news #gastroenterology #hepatology. IF=45.042